Clinical Trials in North Carolina

Showing 9161-9180 of 15,496 trials

A Study of the Effect of a Disease-Specific Migraine Smart Phone Application (App) on Participant Care

NCT03559088

The purpose of this study is to determine whether using a smart phone application to foster communication between study participants and their doctor will impact care. Participants must have a history of migraine or have recently been prescribed a common medicine to treat migraine. The study will last about one year for each participant.

Migraine

Eli Lilly and Company120 participantsStarted Jun 2018

Charlotte, North Carolina, United States • Charlotte, North Carolina, United States • Charlotte, North Carolina, United States +13 more locations

COMPLETEDPhase 325 miles

An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia

NCT02234583

This is an open-label study of DS-5565 in subjects who either completed participation in a preceding Phase 3 study of DS-5565 in fibromyalgia (FM); i.e. DS5565-A-E309 (NCT02146430), DS5565-A-E310 (NCT02187471), or DS5565-A-E311 (NCT02187159) or are de novo subjects. Eligible subjects will be assigned to receive open-label DS-5565 for 52 weeks. All subjects will receive DS-5565 15 mg once daily (QD) for the first three weeks of the treatment period. After three weeks, subjects may be titrated to 15 mg twice daily (BID) based on protocol-specified criteria.

Pain Associated With Fibromyalgia

Daiichi Sankyo2,485 participantsStarted Feb 2015

Birmingham, Alabama, United States • Mobile, Alabama, United States • Phoenix, Arizona, United States +273 more locations

A Study of the Effect of a Disease-Specific Migraine Smart Phone Application (App) on Participant Care

An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia

Find Trials by Condition in North Carolina

A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)

Internet-Delivered Positive Affect Program in Managing Emotion in Young Adult Cancer Survivors

Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD

Nilotinib in Parkinson's Disease

Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Blood and Stool Sample Collection in Subjects Participating in Colorectal Cancer Screening: Act Bold

Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease

A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2

Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects w/o Type 2 Diabetes

A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease

A Safety and Effectiveness Study of JUVÉDERM VOLUMA® XC Injectable Gel for Chin Augmentation

Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I